Treatment of childhood and adolescent mature B-cell lymphoma / 临床儿科杂志
Journal of Clinical Pediatrics
;
(12): 401-404, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-447439
ABSTRACT
Mature B-cell non-Hodgkin lymphoma (B-NHL) represents about 55%-60%of all NHL cases in children and adolescents. Burkitt lymphoma and diffuse large B-cell lymphoma are the most common subtypes. Current combination chemo-therapy regimen succeeds in overall survival rates of more than 80%. Risk factors for the prognosis of childhood and adolescent B-NHL include bone marrow and central nervous system involvement, serum lactate dehydrogenase level and kinetics of re-sponse to therapy. Future strategies should include further understanding of the genetic alternation of B-NHL and utilization of novel target therapies to decrease treatment-related toxicity. We performed a retrospective analysis on the treatment of child and adolescent mature B-cell lymphoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Journal of Clinical Pediatrics
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS